Clinical Trial Update: Evaluation of Safety and Efficacy, Including Pharmacokinetics, of NNC 0129-0000-1003 When Administered for Treatment and Prophylaxis of Bleeding in Subjects With Haemophilia A [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating safety, efficacy, and pharmacokinetics of NNC 0129-0000-1003 for treatment and prophylaxis in Haemophilia A; study completed with resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Haemophilia

Drugs mentioned

• NNC 0129-0000-1003

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Congenital Bleeding Disorder, Haemophilia A | Phase 3 | Status: COMPLETED | Results posted: 2020-04-20